Online citations, reference lists, and bibliographies.
← Back to Search

Acute Antipsychotic Treatment Of Children And Adolescents With Schizophrenia-Spectrum Disorders: A Systematic Review And Network Meta-Analysis.

A. K. Pagsberg, S. Tarp, Dorte Glintborg, A. D. Stenstrøm, A. Fink-Jensen, C. Correll, R. Christensen
Published 2017 · Psychology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
OBJECTIVE To determine the comparative efficacy and safety of antipsychotics for youth with early-onset schizophrenia using network meta-analytic methods combining direct and indirect trial data. METHOD The authors systematically searched MEDLINE, the Cochrane Library, and clinicaltrials.gov and selected randomized controlled trials allocating youth with schizophrenia spectrum disorders to a (non-clozapine) antipsychotic versus placebo or another antipsychotic. Major efficacy outcomes were Positive and Negative Syndrome Scale (PANSS) total and positive symptoms. Major safety outcomes were weight, plasma triglyceride levels, extrapyramidal symptoms, akathisia, and all-cause discontinuation. Sixteen additional outcomes were analyzed. A random-effects arm-based network meta-analysis was applied, and consistency was assessed by pairwise meta-analysis. Confidence in PANSS total estimates was assessed by applying the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. RESULTS Twelve 6- to 12-week trials (N = 2,158; 8-19 years old; 61% boys) involving 8 antipsychotics (aripiprazole, asenapine, paliperidone, risperidone, quetiapine, olanzapine, molindone, and ziprasidone) were analyzed. PANSS total symptom change was comparable among antipsychotics (low- to moderate-quality evidence), except ziprasidone (very low- to low-quality evidence), and all antipsychotics were superior to placebo (low- to high-quality evidence), except ziprasidone and asenapine (low- to moderate-quality evidence). PANSS positive changes and additional efficacy outcomes were comparable among antipsychotics. Weight gain was primarily associated with olanzapine; extrapyramidal symptoms and akathisia were associated with molindone; and prolactin increased with risperidone, paliperidone, and olanzapine. Serious adverse events, discontinuation of treatment, sedation, insomnia, or change in triglycerides did not differ among antipsychotics. CONCLUSION This network meta-analysis showed comparable efficacy among antipsychotics for early-onset schizophrenia, except that efficacy appeared inferior for ziprasidone and unclear for asenapine. Adverse reaction profiles varied substantially among the investigated antipsychotics and were largely consistent with prior findings in adults. Protocol registration information-Antipsychotic Treatment for Children With Schizophrenia Spectrum Disorders: Network Meta-Analysis of Randomised Trials; https://www.crd.york.ac.uk/PROSPERO/; CRD42013006676.
This paper references
10.1089/CAP.2006.16.393
An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia.
T. Mozes (2006)
10.1097/JCP.0b013e3182549259
Adverse Effects of Second-Generation Antipsychotics in Children and Adolescents: A Bayesian Meta-Analysis
D. Cohen (2012)
10.1097/chi.0b013e31815b5cb1
Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes.
C. Correll (2008)
10.1016/S0002-7138(09)61078-5
A depression rating scale for children.
E. Poznanski (1979)
10.1007/s40263-015-0308-1
A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia
R. Harvey (2016)
Antipsychotic medication in adolescents suffering from schizophrenia: a meta-analysis of randomized controlled trials.
Ignazio Ardizzone (2010)
10.1176/appi.ajp.2008.08050756
Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study.
L. Sikich (2008)
10.1136/bmj.f150
Recognition and management of psychosis and schizophrenia in children and young people: summary of NICE guidance
T. Kendall (2013)
10.2307/3001666
The combination of estimates from different experiments.
W. Cochran (1954)
10.1007/s00702-002-0803-7
Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia
D. Gothelf (2003)
10.1097/YCO.0b013e32835dcc2a
Treatment of adolescents with early-onset schizophrenia spectrum disorders: in search of a rational, evidence-informed approach
B. Schimmelmann (2013)
10.1176/appi.ajp.2008.07061035
A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia.
R. Findling (2008)
10.1097/CHI.0b013e3181900404
Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial.
L. Kryzhanovskaya (2009)
10.1186/1471-244X-12-150
A systematic review of the long-term outcome of early onset schizophrenia
L. Clemmensen (2012)
10.1097/YIC.0b013e3283320511
A trial of quetiapine compared with risperidone in the treatment of first onset psychosis among 15- to 18-year-old adolescents
H. Swadi (2010)
10.1016/0197-2456(86)90046-2
Meta-analysis in clinical trials.
R. Dersimonian (1986)
10.1093/ACREFORE/9780199975839.013.104
Diagnostic and Statistical Manual of Mental Disorders
J. Williams (2013)
10.2466/pr0.1962.10.3.799
The Brief Psychiatric Rating Scale
J. Overall (1962)
10.1023/A:1009528727345
The Child and Adolescent Functional Assessment Scale (CAFAS): Review and Current Status
M. Bates (2001)
10.7326/M14-2385
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
B. Hutton (2015)
10.1093/SCHBUL/13.2.261
The positive and negative syndrome scale (PANSS) for schizophrenia.
S. R. Kay (1987)
10.1002/14651858.CD004027.pub2
Antipsychotic medication for childhood-onset schizophrenia.
E. Kennedy (2007)
10.1093/aje/kwp014
Mixed treatment comparison meta-analysis of complex interventions: psychological interventions in coronary heart disease.
N. Welton (2009)
10.1371/journal.pmed.1000100
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
A. Liberati (2009)
10.4088/JCP.11r07064
Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics.
C. Correll (2011)
10.1136/bmjopen-2014-005708
Antipsychotic treatment for children and adolescents with schizophrenia spectrum disorders: protocol for a network meta-analysis of randomised trials
A. K. Pagsberg (2014)
10.1136/bmj.327.7414.557
Measuring inconsistency in meta-analyses
J. Higgins (2003)
10.1007/3-211-31222-6_7
Schizophrenia and related disorders in children and adolescents.
H. Remschmidt (2005)
10.1016/j.eurpsy.2013.08.001
Systematic review of the efficacy and tolerability of clozapine in the treatment of youth with early onset schizophrenia.
C. Schneider (2014)
10.1177/0962280207080643
Evaluation of networks of randomized trials
G. Salanti (2008)
10.1016/S0140-6736(13)60733-3
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
S. Leucht (2013)
10.1517/14740338.2016.1167873
Relationship between antipsychotic medication, serum prolactin levels and osteoporosis/osteoporotic fractures in patients with schizophrenia: a critical literature review
M. De Hert (2016)
10.1089/cap.2015.0027
Safety and Efficacy from an 8 Week Double-Blind Trial and a 26 Week Open-Label Extension of Asenapine in Adolescents with Schizophrenia.
R. Findling (2015)
10.1093/schbul/sbt196
Evidence base for using atypical antipsychotics for psychosis in adolescents.
S. S. Datta (2014)
10.1016/j.jclinepi.2011.01.011
GRADE guidelines: 5. Rating the quality of evidence--publication bias.
G. Guyatt (2011)
10.1111/acps.12459
Relationship between prolactin, breast cancer risk, and antipsychotics in patients with schizophrenia: a critical review
M. De Hert (2016)
10.1517/14740338.2014.906579
Second-generation and newly approved antipsychotics, serum prolactin levels and sexual dysfunctions: a critical literature review
M. De Hert (2014)
10.1503/cmaj.091391
A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview
J. Singh (2009)
10.1016/j.jaac.2014.10.002
Corrected QT changes during antipsychotic treatment of children and adolescents: a systematic review and meta-analysis of clinical trials.
K. G. Jensen (2015)
10.1016/j.biopsych.2011.06.021
A Randomized, Double-Blind Study of Paliperidone Extended-Release in Treatment of Acute Schizophrenia in Adolescents
J. Singh (2011)
10.1136/bmj.d5928
The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials
J. P. Higgins (2011)
10.1089/cap.2012.0068
Ziprasidone in adolescents with schizophrenia: results from a placebo-controlled efficacy and long-term open-extension study.
R. Findling (2013)
10.1016/j.jaac.2014.11.009
Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study.
Adam J. Savitz (2015)
10.1089/cap.2008.0144
A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia.
M. Haas (2009)
10.1111/j.1600-0447.2012.01913.x
Changes in the diagnosed incidence of early onset schizophrenia over four decades
N. Okkels (2013)
10.1136/bmj.g5630
A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis
M. Puhan (2014)
10.1089/cap.2011.0092
Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial.
R. Findling (2012)
10.1016/S0895-4356(97)00049-8
The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials.
H. Bucher (1997)
10.1016/j.ijdevneu.2010.10.003
Childhood onset schizophrenia: support for a progressive neurodevelopmental disorder
J. Rapoport (2011)
10.1192/bjp.bp.107.046177
Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study.
M. Haas (2009)
10.1007/PL00010683
Some remarks on etiological aspects of early-onset schizophrenia
C. Eggers (2009)
10.1089/cap.2007.0123
A comparative pilot study of second-generation antipsychotics in children and adolescents with schizophrenia-spectrum disorders.
J. B. Jensen (2008)
10.1016/j.jclinepi.2010.09.011
GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology.
G. Guyatt (2011)
10.1007/s00787-005-0515-2
Antipsychotics in early onset Schizophrenia
J. Armenteros (2005)
10.1001/ARCHPSYC.1983.01790100074010
A children's global assessment scale (CGAS).
D. Shaffer (1983)
10.1002/SIM.1875
Combination of direct and indirect evidence in mixed treatment comparisons.
G. Lu (2004)



This paper is referenced by
10.1177/2045125318765725
Dilemmas in the treatment of early-onset first-episode psychosis
Daniel Hayes (2018)
Pharmacological interventions in clozapine-refractory schizophrenia
S.R.T. Veerman (2017)
10.1136/ebmental-2018-300040
Twenty years of progress in paediatric psychopharmacology: accomplishments and unmet needs
B. Vitiello (2018)
10.1111/jcpt.12843
Association of dopamine D2 receptor gene polymorphisms with prolactin levels related to risperidone treatment: A systematic review and meta‐analysis
Lingyue Ma (2019)
10.1007/s00228-019-02641-0
The evidence-based choice for antipsychotics in children and adolescents should be guaranteed
D. Putignano (2019)
10.1016/j.jaac.2018.07.891
Meta-Review: Network Meta-Analyses in Child and Adolescent Psychiatry.
S. Cortese (2019)
10.1002/wps.20768
Addressing mental health needs: an integral part of COVID‐19 response
Tedros Adhanom Ghebreyesus (2020)
10.1016/j.euroneuro.2018.03.008
Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: A network meta-analysis
M. Krause (2018)
10.17116/jnevro2019119121132
[Evidence-based treatment of acute psychotic episode and schizophrenia in children and adolescents].
D V Ivashchenko (2019)
10.4103/psychiatry.IndianJPsychiatry_556_18
Clinical Practice Guidelines for the Management of Schizophrenia in Children and Adolescents
S. Grover (2019)
10.1016/j.jaac.2018.01.021
Psychosis in Children and Adolescents.
J. McClellan (2018)
10.3389/fendo.2020.573479
Impact of Psychotropic Medication Effects on Obesity and the Metabolic Syndrome in People With Serious Mental Illness
Victor Mazereel (2020)
Dosing and Monitoring: Children and Adolescents.
G. Hirsch (2018)
10.1016/j.chc.2019.08.009
Psychopharmacologic Treatment of Schizophrenia in Adolescents and Children.
Esther S Lee (2020)
2 Methodological Considerations 2 . 1 Search Strategy and Selection Criteria
S. R. T. Veerman (2017)
10.1016/j.jaac.2019.03.019
Editorial: Making Use of What We Know: Medical Decision-Making and Antipsychotics.
Gail A. Edelsohn (2019)
10.1016/S2215-0366(17)30287-0
Antipsychotics in adolescent-onset psychosis: a work in progress.
A. C. James (2017)
10.1097/JCP.0000000000000747
A Naturalistic Comparison of Methylphenidate and Risperidone Monotherapy in Drug-Naive Youth With Attention-Deficit/Hyperactivity Disorder Comorbid With Oppositional Defiant Disorder and Aggression
G. Masi (2017)
10.1016/j.chc.2019.08.017
Childhood-Onset Schizophrenia and Early-onset Schizophrenia Spectrum Disorders: An Update.
David I Driver (2020)
10.1016/j.jaac.2019.01.015
Cardiometabolic Adverse Effects and Its Predictors in Children and Adolescents With First-Episode Psychosis During Treatment With Quetiapine-Extended Release Versus Aripiprazole: 12-Week Results From the Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis (TEA) Trial.
K. G. Jensen (2019)
10.36927/2079-0325-v27-is2-2019-9
Management of schizophrenia and bipolar disorder in pediatricpractice
I. Martsenkovsky (2019)
10.1007/978-3-030-15541-4_7
Effective Medications for Treating Psychosis in School-Aged Youth
Zachary B. Millman (2019)
10.1007/s40501-018-0137-1
Use of Antipsychotic Drugs for Psychotic Disorders in Children
Shahana Ayub (2018)
10.1016/s2215-0366(20)30296-0
Psychosocial interventions versus antipsychotics forearly-onset psychosis: can we fill the evidence gap?
S. Jauhar (2020)
10.1016/S2215-0366(17)30166-9
Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial.
A. K. Pagsberg (2017)
10.1016/j.ijdevneu.2019.02.002
The development of monoaminergic neurotransmitter systems in childhood and adolescence
M. Pitzer (2019)
10.3390/children7090140
Efficacy of Olanzapine for High and Moderate Emetogenic Chemotherapy in Children
So Rae Lee (2020)
10.1515/dmpt-2020-0102
Pharmacogenetics of antipsychotics in adolescents with acute psychotic episode during first 14 days after admission: effectiveness and safety evaluation.
D. Ivashchenko (2020)
10.1007/978-3-662-59380-6_7
Behandlung unter besonderen Bedingungen (Modul 4c)
W. Gaebel (2019)
10.1016/j.biopha.2020.110707
The impact of quetiapine on the brain lipidome in a cuprizone-induced mouse model of schizophrenia.
C. Zhou (2020)
10.1111/jcpp.13305
Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis.
Rebecca Rodrigues (2020)
10.1007/s00787-020-01563-y
Promoting a patient-centered, transdiagnostic approach to prevention of severe mental illness
M. K. Rimvall (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar